PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma  

作　　者：Chengming Liu Zhanyu Wang Qingpeng Zeng Sufei Zheng Xiaoli Feng Qi Xue Nan Sun Jie He 

机构地区：[1]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [3]Department of Pathology,National Cancer Center/National Clinical Research Centerfor Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《Genes & Diseases》2023年第1期48-50,共3页基因与疾病（英文）

摘　　要：Small-cell lung cancer(SCLC)is a highly malignant cancer with characteristics of rapid growth,abundant angiogenesis,and early distant metastasis that accounts for about 15%of lung cancers.With the wide application of low-dose computed tomography screening in recent years,the incidence of early limited-stage SCLC has increased dramatically.

关 键 词：LUNG cancer METASTASIS 

分 类 号：R734.2[医药卫生—肿瘤]